Neuromodulation Market: Rising Awareness on Neurodegenerative Disorders

Neuromodulation Market

According to the new market research report “Neuromodulation Market by Technology- Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation), Application (Ischemia, Chronic Pain, Parkinson’s, Depression, Tremor, Epilepsy, Migraine) – Global Forecast to 2025“.

The global neuromodulation market is projected to reach USD 8.8 billion by 2025 from USD 5.8 billion in 2020, at a CAGR of 8.6% between 2020 and 2025. The growth of this market is driven majorly by the rising prevalence of neurological disorders, increasing research into expanding the applications of neuromodulation, and awareness on neurodegenerative disorders. However, the high cost of neuromodulation procedures and equipment, along with the dearth of a trained workforce, is expected to restrain the growth of this market during the forecast period.

Neuromodulation Market

In 2019, Parkinson’s disease held the largest share of the deep brain stimulation market, by application

Based on application, the deep brain stimulation market is segmented into Parkinson’s disease, tremor, depression, and other DBS applications. Parkinson’s disease accounted for the largest share of this market in 2019. The growth of this segment is attributed to the rising incidence of the disease and growing R&D activity in this area.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=921

By Technology

  • Internal Neuromodulation
    • Spinal Cord Stimulation
    • Deep Brain Stimulation
    • Vagus Nerve Stimulation
    • Sacral Nerve Stimulation
    • Gastric Electrical Stimulation
  • External Neuromodulation
    • Transcutaneous Electrical Nerve Stimulation (TENS)
    • Transcranial Magnetic Stimulation (TMS)
    • Respiratory Electrical Stimulation (RES)

By Application

  • Spinal Cord Stimulation Market, By Application
    • Failed Back Syndrome
    • Chronic Pain
    • Ischemia
  • Deep Brain Stimulation Market, By Application
    • Parkinson’s Disease
    • Tremor
    • Depression
    • Other DBS Applications
  • Sacral Nerve Stimulation Market, By Application
    • Urine Incontinence
    • Fecal Incontinence
  • Vagus Nerve Stimulation Market, By Application
    • Epilepsy
    • Other VNS Applications
  • Gastric Electrical Stimulation Market, By Application
    • Gastroparesis
    • Obesity
  • Transcutaneous Electrical Nerve Stimulation Market, By Application
    • Treatment-resistant Depression
    • Other TENS Applications
  • Transcranial Magnetic Stimulation Market, By Application
    • Depression
    • Migraine Headache
  • Respiratory Electrical Stimulation Market, By Application
    • Spinal Cord Injury
Neuromodulation Market

The Asia Pacific neuromodulation market is expected to grow at the highest CAGR during the forecast period

The Asia Pacific is expected to grow at the highest rate in the market. The major factors driving the growth of this market include the high incidence of neurological disorders, increasing public and private investments, and ongoing research.

Request for Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=921

Key Market Players

The prominent players in the neuromodulation market include Medtronic (Ireland), Boston Scientific Corporation (US), Abbott (US), LivaNova (UK), Synapse Biomedical, Inc. (US), Nevro Corporation (US), NeuroSigma (US), NeuroPace (US), Neuronetics (US), and BioControl Medical (Israel). Major players have focused on product launches, agreements, and partnerships to increase their shares in the global market.

Medtronic is one of the leading players in the market. The company’s leading position can be attributed to its wide portfolio of neuromodulation devices and strong geographical footprint. The company operates in the US, Europe, and the Asia Pacific. It serves clinicians, physicians, hospitals, and patients in more than 160 countries. R&D is a key area of focus for Medtronic—it invested USD 2,330 million in 2019, as compared to USD 2,256 million in 2018 and USD 2,193 million in 2017. The company also focuses on organic as well as inorganic growth strategies to gain a competitive edge.

Recent Developments

  • In 2019, NeuroSigma signed a partnership agreement with Teijin Limited (Teijin) (Japan). The partnership granted Teijin Pharma, the core company of Teijin’s healthcare business, exclusive rights to market NeuroSigma’s Monarch eTNS system in Japan, as well as the company’s TNS patent rights in Japan related to the non-invasive treatment of ADHD.
  • In 2018, Abbott signed an agreement with the National Institutes of Health (NIH) (US). As per the agreement, Abbott will provide neuromodulation technologies, including directional DBS, SCS, and DRG therapy, for NIH research to explore their applications in chronic pain and progressive movement disorders.
  • In 2017, Medtronic signed a partnership agreement with Mercy (US) to establish a new data sharing and analysis network that helps gather clinical evidence for medical device innovation and patient access

Critical questions answered in the report:

  • Which regions are likely to grow at the highest CAGR?
  • What are the recent trends affecting the neuromodulation market?
  • Who are the key players in the market, and how intense is the competition?
  • What are the application areas of neuromodulation devices?
  • What are the challenges hindering the adoption of neuromodulation devices?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst